1 Holdaway IM, 89 : 667-674, 2004
2 Murray RD, "a critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly" 93 : 2957-2968, 2008
3 Roelfsema F, "Therapeutic options in the management of acromegaly: focus on lanreotide Autogel" 2 : 463-479, 2008
4 Ashwell SG, "The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR" 150 : 473-480, 2004
5 van Thiel SW, "Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients" 150 : 489-495, 2004
6 McKeage K, "Octreotide long-acting release (LAR): a review of its use in the management of acromegaly" 63 : 2473-2499, 2003
7 Orme SM, "Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group" 83 : 2730-2734, 1998
8 Feelders RA, "Medical therapy of acromegaly: efficacy and safety of somatostatin analogues" 69 : 2207-2226, 2009
9 Melmed S, "Medical progress: acromegaly" 355 : 2558-2573, 2006
10 Ayuk J, "Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly" 89 : 1613-1617, 2004
1 Holdaway IM, 89 : 667-674, 2004
2 Murray RD, "a critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly" 93 : 2957-2968, 2008
3 Roelfsema F, "Therapeutic options in the management of acromegaly: focus on lanreotide Autogel" 2 : 463-479, 2008
4 Ashwell SG, "The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR" 150 : 473-480, 2004
5 van Thiel SW, "Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients" 150 : 489-495, 2004
6 McKeage K, "Octreotide long-acting release (LAR): a review of its use in the management of acromegaly" 63 : 2473-2499, 2003
7 Orme SM, "Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group" 83 : 2730-2734, 1998
8 Feelders RA, "Medical therapy of acromegaly: efficacy and safety of somatostatin analogues" 69 : 2207-2226, 2009
9 Melmed S, "Medical progress: acromegaly" 355 : 2558-2573, 2006
10 Ayuk J, "Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly" 89 : 1613-1617, 2004
11 Alexopoulou O, "Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR" 151 : 317-324, 2004
12 Turner HE, "A comparison of lanreotide and octreotide LAR for treatment of acromegaly" 51 : 275-280, 1999
13 Cozzi R, "A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly" 141 : 267-271, 1999
14 Andries M, "A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly" 68 : 473-480, 2008